ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGEN vs ARTV // GROSS PROFIT MARGIN

Compugen Ltd. (NASDAQ) VS. Artiva Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CGEN 3 — ARTV 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. ARTV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGEN ARTV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 87.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 CGEN /roic <GO>
EV/EBITDA & P/E Valuation 3.2x — — TIE /valuation <GO>
Free Cash Flow Yield 16.24% — — TIE /fcf-yield <GO>
Operating Margin 43.10% — — TIE /operating-margins <GO>
Net Profit Margin 48.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) 161.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.03 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 CGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.1 20.6 +20.49 CGEN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 4.6x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $193.0M $206.8M -$13.9M ARTV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGEN REV ARTV REV CGEN GROSS % ARTV GROSS % CGEN FCF ARTV FCF
FY 2025 $72.8M $0 87.3% — $31.3M -$79.3M
FY 2024 $27.9M $251.0K 71.5% — $49.5M -$55.7M
FY 2023 $33.5M $32.9M — — -$35.9M -$47.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
ARTV // BETA —